Tributyrin for early acute pancreatitis
Part of Digestive system clinical trials.
This trial tests a supplement called tributyrin (related to butyrate) to see if it can help prevent complications from acute pancreatitis when given early after diagnosis. It is for people having their first episode of pancreatitis, not for those with certain causes or weakened immune systems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having your first episode of acute pancreatitis.
- You have been diagnosed less than 24 hours ago (or symptoms started less than 72 hours ago).
- Your pancreatitis was not caused by an endoscopy, cancer, injury, or surgery.
- You do not have a weakened immune system or take immune-suppressing medicines.
- You are 18 years or older and not pregnant or breastfeeding.
- You have not had repeated or chronic pancreatitis in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking a probiotic called Bifidobacterium longum can help people with acute pancreatitis recover better. The study compares the probiotic against a placebo (a pill with no active ingredient) to see if it reduces inflammation and complications.
This trial tests an investigational medicine called SGC001 given as an injection to people with severe acute pancreatitis, a serious inflammation of the pancreas. The study aims to see if the drug is safe and helpful, and to gather early information on how it works.
This trial tests infliximab (an anti-inflammatory medicine) versus placebo to see if it improves outcomes in adults with newly diagnosed acute pancreatitis. It is designed for treatment to start within 36 hours of hospital admission.
This trial tests whether a fecal microbiota transplant (FMT) can help prevent infections in people with moderately severe or severe acute pancreatitis. You may qualify if you are between 18 and 75, have had pancreatitis for 15 to 21 days, and already have a feeding tube in place.
This trial tests whether a drug called tacrolimus can reduce the risk of pancreatitis (inflammation of the pancreas) after a procedure called ERCP, which is used to diagnose and treat problems in the bile ducts or pancreas. If you are scheduled for an ERCP, this study may help prevent a common complication.
This trial tests if adding a probiotic (Bacillus subtilis and Enterococcus faecium) to standard lipid-lowering therapy helps people with mild pancreatitis caused by very high triglycerides. It aims to see if the combination reduces inflammation and speeds recovery.
Hear when a new Acute Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.